Subtype best predictor of basal cell carcinoma invasion depth

Share this article:
Subtype Best Predictor of Basal Cell Carcinoma Invasion Depth
Subtype Best Predictor of Basal Cell Carcinoma Invasion Depth

(HealthDay News) -- Basal cell carcinoma (BCC) subtype identified on biopsy and excision specimens is the best predictor of depth of invasion, according to a study published online April 16 in the Journal of the American Academy of Dermatology.

Michael Jude Welsch, M.D., from the Penn State Milton S. Hershey Medical Center, and colleagues studied histologic specimens from 100 BCC biopsy samples. Anatomic site; histologic subtype; maximum depth of extension; contour of the lobules at the leading edge; elastosis features; and the incidence of necrosis, calcification, and ulceration were noted, and their correlation with depth of invasion was assessed.

The researchers found 62 percent concordance between the subtype of biopsy and excision specimen. The greatest mean depth was seen for micronodular tumors, followed by infiltrative, nodular, and superficial subtypes. Depth was significantly correlated to subtype from biopsy and excision, and this association was superior to age, contours of the excision specimens, presence of necrosis, and the extent of excisional solar elastosis. Depth was not correlated with gender, anatomic site, contours of biopsy specimens, elastosis color, elastosis type, the presence of ulceration, or calcification.

"Morphologic subtype has the highest correlation with depth and reporting should reflect the highest risk growth pattern if a biopsy specimen contains more than one pattern," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Bisphosphonate use may not prevent breast cancer

Bisphosphonate use may not prevent breast cancer

Data from two randomized controlled trials suggest that bisphosphonate use does not protect against postmenopausal breast cancer, according to research.

Patients with Medicaid or no coverage show higher cancer mortality

Patients with Medicaid or no coverage show higher ...

Patients with Medicaid insurance or no insurance coverage are less likely to receive cancer-related surgery and/or radiation and are more likely to die from cancer than those with insurance, according ...

Once-only flexible sigmoidoscopy screening lowers colorectal cancer incidence

Once-only flexible sigmoidoscopy screening lowers colorectal cancer incidence

Once-only flexible sigmoidoscopy screening, with or without fecal occult blood testing (FOBT), is associated with reduced colorectal cancer incidence and mortality, according to a study.